메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview

[ 메디채널 김갑성 기자 ] Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 -- BestQool , a pioneer manufacturer of home-use red light therapy devices, is excited to unveil its latest breakthrough product – the BQ60Pro. Based on years of experience and customer feedback, this small yet powerful home-use device now provides six wavelengths for maximum therapeutic protocols, high power output, and a versatile mounting system that completely redefines flexibility in home light therapy. Ahead of the Fall release, BestQool will be holding its Summer Appre
- 김갑성 기자
- 2025-08-15 21:00
Tie "James" Li, Chairman of NMHI, To Speak at XRP Seoul 2025 Global Conference

ONTARIO, Calif., Aug. 15, 2025 -- Tie "James" Li, Chairman and CEO of Nature's Miracle Holding Inc. (OTCQB:NMHI) will attend the XRP Seoul 2025 Global Conference as a keynote speaker on September 21, 2025. XRP SEOUL 2025 hosted by XRPL Korea is a global conference bringing together XRP holders, developers, and ecosystem projects from around the world. Taking place on September 21, 2025, the event features sessions on market outlooks, Web3 go-to-market strategies, and the evolving regulatory landscape. There will be over 3,000 attendees and over 100 compa
- 황정호 기자
- 2025-08-15 20:30
Novel Gene Therapy for ALS cleared for global trials in China and the U.S.

BEIJING, Aug. 15, 2025 -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today that China's National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for SNUG01, a groundbreaking gene therapy product for amyotrophic lateral sclerosis (ALS). This milestone follows a prior clearance of SNUG01's IND application by the U.S. Food and Drug Administration (FDA) in March 2025, paving the way for the initiation of a Phase I/IIa mul
- 김갑성 기자
- 2025-08-15 19:00
Saigon Technology Drives Industry-Specific AI Transformation, Moving Businesses Beyond SaaS Limitations

[ 메디채널 김갑성 기자 ] Vietnamese software leader leverages AI and domain expertise to help industries modernize workflows and reduce long-term tech costs. HO CHI MINH CITY, Vietnam, Aug. 15, 2025 -- As global businesses outgrow generic SaaS tools, Saigon Technology is delivering next-gen, AI-powered custom software for healthcare, fintech, logistics, and e-commerce — unlocking productivity and digital resilience. According to a 2024 report by Vietnam's Ministry of Science and Technology, digital adoption among local businesses surged from 30% in 2021 to nearly 70% in 2024. Many of t
- 김갑성 기자
- 2025-08-15 10:00
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

Shanghai, Aug. 15, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the "Updated Guidelines"). In patients with moderately to severely active ulcerative colitis (UC), the updated guidelines recommend S1P receptor modulators, including etrasimod, are recommended for induct
- 김갑성 기자
- 2025-08-15 09:35
CARsgen Therapeutics Announces 2025 Interim Results

SHANGHAI, Aug. 15, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results. Business Highlights Cash and bank balances were around RMB1,261 million as of June 30, 2025. Cash and cash equivalents and deposits at the end of 2025 are expected to be not less than RMB1,100 million. We expect to have adequate cash into the 2028 excluding subsequent cash inflows. During H1 2025, certification and regulatory filings for zevor-cel have been completed in more t
- 김갑성 기자
- 2025-08-15 08:15
TraceLink Accelerates Supply Chain Transformation with New OPUS Platform Capabilities for an AI-Powered Future

BOSTON, Aug. 14, 2025 -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, today announced significant new platform enhancements to drive supply chain transformation with its Orchestration Platform for Universal Solutions (OPUS). The new capabilities are designed to empower supply chain, finance, commercial, and IT leaders to master today's supply chain complexities and prepare for an agentic-first future. The platform and product releases—spanning OPUS, Multienterprise Information Network
- 김갑성 기자
- 2025-08-14 22:00
Sisram Medical will Report H1 2025 Financial Results on August 20 and Hold a Conference Call on August 21

[ 메디채널 김갑성 기자 ] H1 2025 conference call to be held on August 21, at 8:30 a.m. Eastern Time HONG KONG, Aug. 14, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred to as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused brands, including energy-based devices, injectables, and other complementary offerings, today announced that it expects to release its financial results for H1 2025, ended June 30
- 김갑성 기자
- 2025-08-14 20:00
Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma

NANJING, China, Aug. 14, 2025 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LBL-024), a novel PD-L1/4-1BB bispecific antibody. This marks the world's first registrational clinical trial evaluating an immunotherapy monotherapy for extrapulmonary neuroendocrine carcinoma (EP-NEC). The study, led by Professor Shen Lin from Peking University Cancer Hospital and conduc
- 김갑성 기자
- 2025-08-14 17:38
Clarivate Launches AI-powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory Burden

[ 메디채널 김갑성 기자 ] Integrated into Cortellis Regulatory Intelligence, new AI capability helps regulatory teams streamline access to critical intelligence and understand requirements with ease LONDON, Aug. 14, 2025 -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the beta launch of its AI-powered Regulatory Assistant within Cortellis Regulatory Intelligence. This new capability is designed to help regulatory professionals navigate complex and evolving global requirements with greater ease, speed and confidence. Informed by customer i
- 김갑성 기자
- 2025-08-14 15:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 31일 01시 20분